The Journal of Urology· 2012Q1
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
- 407citations
- Q1SCImago
- 2012year
Short summary
OnabotulinumtoxinA (100 U) significantly reduced daily urinary incontinence episodes by an average of 2.65 vs. 0.87 for placebo, and achieved complete continence in 22.9% of patients vs. 6.5% in a Phase 3 trial (n=557).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Urology
UrologyMedicine